Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

BACKGROUND: Bevacizumab plus chemotherapy prolongs progression-free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC). Although there is strong evidence to suggest that the mutational status of the K-ras oncogene has a role as a predictive factor for activity in patient...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Rossi, Luigi, Veltri, Enzo, Zullo, Angelo, Zoratto, Federica, Colonna, Maria, Longo, Flavia, Mottolese, Marcella, Giannarelli, Diana, Ruco, Luigi, Marchetti, Paolo, Romiti, Adriana, Barucca, Viola, Giannini, Giuseppe, Bianchi, Loredana, Tomao, Silverio
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2013
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3848929/
https://ncbi.nlm.nih.gov/pubmed/24348051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S43828
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы